Floatz logo

ETOPOSIDE

Neuroblastoma

M.D. Anderson Cancer CenterSmall moleculePhase 2/3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

63 Active assets in the Neuroblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 4BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Robbie Majzner
Phase 2BB
Carboplatin
St. Jude Children's Research Hospital
Phase 2/3BB

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →